Literature DB >> 24582309

Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype.

Eunice Ching Chan1, Yun Bai1, Arnold S Kirshenbaum1, Elizabeth R Fischer2, Olga Simakova3, Geethani Bandara1, Linda M Scott1, Laura B Wisch1, Daly Cantave1, Melody C Carter1, John C Lewis4, Pierre Noel5, Irina Maric3, Alasdair M Gilfillan1, Dean D Metcalfe1, Todd M Wilson6.   

Abstract

BACKGROUND: Mastocytosis associated with germline KIT activating mutations is exceedingly rare. We report the unique clinicopathologic features of a patient with systemic mastocytosis caused by a de novo germline KIT K509I mutation.
OBJECTIVES: We sought to investigate the effect of the germline KIT K509I mutation on human mast cell development and function.
METHODS: Primary human mast cells derived from CD34(+) peripheral blood progenitors were examined for growth, development, survival, and IgE-mediated activation. In addition, a mast cell transduction system that stably expressed the KIT K509I mutation was established.
RESULTS: KIT K509I biopsied mast cells were round, CD25(-), and well differentiated. KIT K509I progenitors cultured in stem cell factor (SCF) demonstrated a 10-fold expansion compared with progenitors from healthy subjects and developed into mature hypergranular mast cells with enhanced antigen-mediated degranulation. KIT K509I progenitors cultured in the absence of SCF survived but lacked expansion and developed into hypogranular mast cells. A KIT K509I mast cell transduction system revealed SCF-independent survival to be reliant on the preferential splicing of KIT at the adjacent exonic junction.
CONCLUSION: Germline KIT mutations associated with mastocytosis drive a well-differentiated mast cell phenotype distinct to that of somatic KIT D816V disease, the oncogenic potential of which might be influenced by SCF and selective KIT splicing. Published by Mosby, Inc.

Entities:  

Keywords:  K509I; KIT; germline; mast cells; mastocytosis; well differentiated

Mesh:

Substances:

Year:  2014        PMID: 24582309      PMCID: PMC4125511          DOI: 10.1016/j.jaci.2013.12.1090

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  38 in total

1.  Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis.

Authors:  Iván Alvarez-Twose; Pablo González; José Mário Morgado; María Jara-Acevedo; Laura Sánchez-Muñoz; Almudena Matito; Manuela Mollejo; Alberto Orfao; Luis Escribano
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

2.  Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.

Authors:  Todd M Wilson; Irina Maric; Olga Simakova; Yun Bai; Eunice Ching Chan; Nicolas Olivares; Melody Carter; Dragan Maric; Jamie Robyn; Dean D Metcalfe
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

Review 3.  Mast cells and mastocytosis.

Authors:  Dean D Metcalfe
Journal:  Blood       Date:  2008-08-15       Impact factor: 22.113

Review 4.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

5.  Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.

Authors:  Cristina Teodosio; Andrés C García-Montero; María Jara-Acevedo; Laura Sánchez-Muñoz; Ivan Alvarez-Twose; Rosa Núñez; Lawrence B Schwartz; Andrew F Walls; Luis Escribano; Alberto Orfao
Journal:  J Allergy Clin Immunol       Date:  2010-01-12       Impact factor: 10.793

Review 6.  A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions.

Authors:  Zhuwei Xu; Boquan Jin
Journal:  Cell Mol Immunol       Date:  2010-01       Impact factor: 11.530

7.  Generation, isolation, and maintenance of human mast cells and mast cell lines derived from peripheral blood or cord blood.

Authors:  Madeleine Rådinger; Bettina M Jensen; Hye Sun Kuehn; Arnold Kirshenbaum; Alasdair M Gilfillan
Journal:  Curr Protoc Immunol       Date:  2010-08

8.  Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis.

Authors:  Bartosz Wasag; Marek Niedoszytko; Anna Piskorz; Magdalena Lange; Joanna Renke; Ewa Jassem; Wojciech Biernat; Maria Debiec-Rychter; Janusz Limon
Journal:  Exp Hematol       Date:  2011-05-27       Impact factor: 3.084

9.  Evaluation of the WHO criteria for the classification of patients with mastocytosis.

Authors:  Laura Sánchez-Muñoz; Ivan Alvarez-Twose; Andrés C García-Montero; Cristina Teodosio; María Jara-Acevedo; Carlos E Pedreira; Almudena Matito; Jose Mario T Morgado; Maria Luz Sánchez; Manuela Mollejo; David Gonzalez-de-Olano; Alberto Orfao; Luis Escribano
Journal:  Mod Pathol       Date:  2011-05-06       Impact factor: 7.842

10.  The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.

Authors:  M Pedersen; L Rönnstrand; J Sun
Journal:  Cell Signal       Date:  2008-11-17       Impact factor: 4.315

View more
  15 in total

1.  An optimized protocol for the generation and functional analysis of human mast cells from CD34+ enriched cell populations.

Authors:  Yuzhi Yin; Yun Bai; Ana Olivera; Avanti Desai; Dean D Metcalfe
Journal:  J Immunol Methods       Date:  2017-06-16       Impact factor: 2.303

Review 2.  Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.

Authors:  Peter Valent; Cem Akin; Karin Hartmann; Gunnar Nilsson; Andreas Reiter; Olivier Hermine; Karl Sotlar; Wolfgang R Sperr; Luis Escribano; Tracy I George; Hanneke C Kluin-Nelemans; Celalettin Ustun; Massimo Triggiani; Knut Brockow; Jason Gotlib; Alberto Orfao; Lawrence B Schwartz; Sigurd Broesby-Olsen; Carsten Bindslev-Jensen; Petri T Kovanen; Stephen J Galli; K Frank Austen; Daniel A Arber; Hans-Peter Horny; Michel Arock; Dean D Metcalfe
Journal:  Cancer Res       Date:  2017-03-02       Impact factor: 12.701

Review 3.  Mechanisms controlling mast cell and basophil lineage decisions.

Authors:  Hua Huang; Yapeng Li
Journal:  Curr Allergy Asthma Rep       Date:  2014-09       Impact factor: 4.806

Review 4.  Chronic mast cell leukemia: a novel leukemia-variant with distinct morphological and clinical features.

Authors:  Peter Valent; Karl Sotlar; Wolfgang R Sperr; Andreas Reiter; Michel Arock; Hans-Peter Horny
Journal:  Leuk Res       Date:  2014-09-30       Impact factor: 3.156

Review 5.  Pediatric Mastocytosis: Recognition and Management.

Authors:  Julie V Schaffer
Journal:  Am J Clin Dermatol       Date:  2021-03       Impact factor: 7.403

Review 6.  Syndromic gastrointestinal stromal tumors.

Authors:  Riccardo Ricci
Journal:  Hered Cancer Clin Pract       Date:  2016-07-19       Impact factor: 2.857

Review 7.  Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis.

Authors:  Hengning Ke; Julhash U Kazi; Hui Zhao; Jianmin Sun
Journal:  Cell Biosci       Date:  2016-10-18       Impact factor: 7.133

8.  Well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: A case report.

Authors:  Lanshan Huang; Sa A Wang; Sergej Konoplev; Carlos E Bueso-Ramos; Beenu Thakral; Roberto N Miranda; Elias Jabbour; L Jeffrey Medeiros; Rashmi Kanagal-Shamanna
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

9.  Immunophenotypic and Ultrastructural Analysis of Mast Cells in Hermansky-Pudlak Syndrome Type-1: A Possible Connection to Pulmonary Fibrosis.

Authors:  Arnold S Kirshenbaum; Glenn Cruse; Avanti Desai; Geethani Bandara; Maarten Leerkes; Chyi-Chia R Lee; Elizabeth R Fischer; Kevin J O'Brien; Bernadette R Gochuico; Kelly Stone; William A Gahl; Dean D Metcalfe
Journal:  PLoS One       Date:  2016-07-26       Impact factor: 3.240

10.  Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature.

Authors:  Iván Alvarez-Twose; Almudena Matito; José Mário Morgado; Laura Sánchez-Muñoz; María Jara-Acevedo; Andrés García-Montero; Andrea Mayado; Carolina Caldas; Cristina Teodósio; Javier Ignacio Muñoz-González; Manuela Mollejo; Luis Escribano; Alberto Orfao
Journal:  Oncotarget       Date:  2016-07-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.